CoChat

The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity

Palakurthi, Sangeetha, Kuraguchi, Mari, Zacharek, Sima J., Zudaire, Enrique, Huang, Wei, Bonal, Dennis M., Liu, Jeffrey, Dhaneshwar, Abha, DePeaux, Kristin, Gowaski, Martha R., Bailey, Dyane, Regan, Samuel N., Ivanova, Elena, Ferrante, Catherine, English, Jessie M., Khosla, Aditya, Beck, Andrew H., Rytlewski, Julie A., Sanders, Catherine, Laquerre, Sylvie, Bittinger, Mark A., Kirschmeier, Paul T., Packman, Kathryn, Janne, Pasi A., Moy, Christopher, Wong, Kwok-Kin, Verona, Raluca I., Lorenzi, Matthew V. · 2019 · Cancer Immunology Research
Cited by 147

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

The success of targeted or immune therapies is often hampered by the emergence of resistance and/or clinical benefit in only a subset of patients. We hypothesized that combining targeted therapy with immune modulation would show enhanced antitumor responses. Here, we explored the combination potential of erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor under clinical development, with PD-1 blockade in an autochthonous FGFR2K660N/p53mut lung cancer mouse model. Erdafitinib monotherapy treatment resulted in substantial tumor control but no significant survival benefit. Although anti–PD-1 alone was ineffective, the erdafitinib and anti–PD-1 combination induced significant tumor regression and improved survival. For both erdafitinib monotherapy and combination treatments, tumor control was accompanied by tumor-intrinsic, FGFR pathway inhibition, increased T-cell infiltration, decreased regulatory T cells, and downregulation of PD-L1 expression on tumor cells. These effects were not observed in a KRASG12C-mutant genetically engineered mouse model, which is insensitive to FGFR inhibition, indicating that the immune changes mediated by erdafitinib may be initiated as a consequence of tumor cell killing. A decreased fraction of tumor-associated macrophages also occurred but only in combination-treated tumors. Treatment with erdafitinib decreased T-cell receptor (TCR) clonality, reflecting a broadening of the TCR repertoire induced by tumor cell death, whereas combination with anti–PD-1 led to increased TCR clonality, suggesting a more focused antitumor T-cell response. Our results showed that the combination of erdafitinib and anti–PD-1 drives expansion of T-cell clones and immunologic changes in the tumor microenvironment to support enhanced antitumor immunity and survival.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-18-0595

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 147

Metadata

Authors
Palakurthi, S., Kuraguchi, M., Zacharek, S. J., Zudaire, E., Huang, W., Bonal, D. M., Liu, J., Dhaneshwar, A., DePeaux, K., Gowaski, M. R., Bailey, D., Regan, S. N., Ivanova, E., Ferrante, C., English, J. M., Khosla, A., Beck, A. H., Rytlewski, J. A., Sanders, C., Laquerre, S., Bittinger, M. A., Kirschmeier, P. T., Packman, K., Janne, P. A., Moy, C., Wong, K.-K., Verona, R. I., & Lorenzi, M. V.
Venue
Cancer Immunology Research
Published
2019-09-01
Volume
7
Issue
9
Pages
1457-1471
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2963572064
Cited by
147
References
11
FWCI
7.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0595
The paper
Palakurthi, S., Kuraguchi, M., Zacharek, S. J., Zudaire, E., Huang, W., Bonal, D. M., Liu, J., Dhaneshwar, A., DePeaux, K., Gowaski, M. R., Bailey, D., Regan, S. N., Ivanova, E., Ferrante, C., English, J. M., Khosla, A., Beck, A. H., Rytlewski, J. A., Sanders, C., . . . Lorenzi, M. V. (2019). The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0595

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.